In this short interview, CEO Witty of Glaxo – British multinational pharmaceutical, biologics, vaccines and consumer healthcare company – said that while Chinese government will continue to have a tension between building its domestic industry and fomenting an open competitive market in which foreign companies participates, it does a good job of making its market fair. Most importantly, Witty notes that it’s important to take a long-term view when it comes to China. Glaxo intends to embed its Chinese operations into an integral part of the company. You won’t be that successful if you just take a “tourist” of China, he said. Witty says Glaxo intends to profit as well as to innovate in China.
Categories: Analysis, economy, Interview, News, politics, q&a, technology, video Tags: GlaxoSmithKline, innovation, intellectual property, international trade, r&d, Sir Andrew Witty - Chief Executive Officer
Professor Ann Lee
Ann Lee, a former investment banker and hedge fund partner, and now an adjunct professor of economics and finance at New York University, recently sat down with Allen and I for a conversation about her book, “What the U.S. Can Learn from China.” (Also in our Recommend Read section.)
She discussed some lessons and also gave us her views about the misinformation in the U.S. media on various issues of contention between the U.S. and China. For example, as an insider at Wall Street, she was able to give an illuminating rundown of the ‘currency manipulation’ charge laid against China.
This article is a transcript of that conversation, edited slightly for readability. Allen plans to do a book review, but first, we’d like to share some endorsements and accolades she has already garnered for it: Read more…
Recent Comments